NCT05710380 MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
| NCT ID | NCT05710380 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2023-04-26 |
| Primary Completion | 2029-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2023-04-26 with a primary completion date of 2029-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.
Eligibility Criteria
Inclusion Criteria: * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate. * Voluntary written informed consent before the MRI examination. Exclusion Criteria: * Subjects incapable of giving informed written consent. * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. * Prisoners. * Minor children (under the age of 18 years old). * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.
Contact & Investigator
Aytekin Oto, MD
STUDY CHAIR
University of Chicago Medicine Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT05710380 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05710380 currently recruiting?
Yes, NCT05710380 is actively recruiting participants. Contact the research team at aoto@radiology.bsd.uchicago.edu for enrollment information.
Where is the NCT05710380 trial being conducted?
This trial is being conducted at Chicago, United States, Portland, United States.
Who is sponsoring the NCT05710380 clinical trial?
NCT05710380 is sponsored by University of Chicago. The principal investigator is Aytekin Oto, MD at University of Chicago Medicine Comprehensive Cancer Center. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.